|
J Biol Chem, Vol. 275, Issue 4, 2636-2646, January 28, 2000
Cholesterol 3-Sulfate Interferes with Cornified Envelope Assembly
by Diverting Transglutaminase 1 Activity from the Formation of
Cross-links and Esters to the Hydrolysis of Glutamine*
Zoltán
Nemes ,
Máté
Demény§,
Lyuben N.
Marekov ,
László
Fésüs§, and
Peter M.
Steinert ¶
From the Laboratory of Skin Biology, NIAMSD, National
Institutes of Health, Bethesda, Maryland 20892-2752 and the
§ Department of Biochemistry and Molecular Biology,
University Medical School of Debrecen, Debrecen H-4012, Hungary
 |
ABSTRACT |
The loss of transglutaminase 1 enzyme (TGase 1)
activity causes lamellar ichthyosis. Recessive X-linked ichthyosis (XI)
results from accumulation of excess cholesterol 3-sulfate
(CSO4) in the epidermis but the pathomechanism how
elevated epidermal CSO4 causes ichthyosis is largely
unknown. Here we provide evidence that XI is also a consequence of
TGase 1 dysfunction. TGase 1 is a key component of barrier formation in
keratinocytes: it participates in the cross-linking of cell envelope
(CE) structural proteins, and also forms the lipid bound envelope by
esterification of long chain -hydroxyceramides onto CE proteins.
Using involucrin and an epidermal -hydroxyceramide analog as
substrates, kinetic analyses revealed that at membrane concentrations
above 4 mol %, CSO4 caused a marked and
dose-dependent inhibitory effect on isopeptide and ester
bond formation. Sequencing of tryptic peptides from TGase 1-reacted
involucrin showed a large increase in deamidation of substrate
glutamines. We hypothesize that supraphysiological levels of
CSO4 in keratinocyte membranes distort the structure of
TGase 1 and facilitate the access of water into its active site causing hydrolysis of substrate glutamine residues. Our findings provide further evidence for the pivotal role of the TGase 1 enzyme in CE formation.
 |
INTRODUCTION |
Assembly of an effective epidermal barrier structure is an
essential adaptation to terrestrial life. In mammals the outermost bulwark of this barrier is the cornified layer of the epidermis, composed of flattened corneocytes mortared together by orderly lipid
laminae. During terminal differentiation, individual corneocytes acquire a specialized cell peripheral structure termed the cornified cell envelope (CE),1 which is
responsible for maintenance of mechanical and chemical protection and
indirectly contributes to water permeability barrier (see Refs. 1 and
2, for reviews). The CE is composed of two parts. The ~10 nm thick
protein envelope is formed by covalent cross-linking of several
structural proteins by sulfhydryl oxidases and transglutaminases
(TGases). This highly insoluble protein meshwork is coated by the lipid
envelope, a ~5 nm thick layer of -hydroxyceramides with uniquely
long (C28-C36) fatty acyl moieties (3). These
are covalently attached by ester bonds through their -hydroxyl group
to selected glutamines to envoplakin, periplakin, and involucrin
components of the protein envelope (4).
Terminal differentiation of keratinocytes is accompanied by vigorous
lipid metabolism and synthesis of keratinization-specific lipids in the
granular layer. Newly synthesized lipids are temporarily stored in
cytoplasmic lamellar bodies, in which they are arranged as stacks of
tetralaminar sheets. The lamellar body lipids consist largely of free
fatty acids, (glucosyl)ceramides, cholesterol, and its acyl or sulfate
esters (3). In the uppermost granular layer the lamellar bodies fuse
with the cell membrane, and release their contents which assume broad,
multilamellar lipid sheets between corneocytes. This process
approximately coincides with the initiation of assembly of both the
protein envelope and lipid envelope of the CE (5). It is thought that
the ester-linked long chain -hydroxyceramides comprising the lipid
bound envelope interdigitate with the interstitial lipid layers and
might function in a Velcro-like fashion by fixing the protein envelope
to surrounding lipid structures, and vice versa. In this
way, the lipid bound envelope contributes to the maintenance of an
orderly array of lipid layers during normal wear and tear and
mechanical stress of the epidermis.
Genetic errors of CE and skin barrier formation can manifest as
ichthyosiform symptoms. Some of these diseases have been distinguished on the basis of abnormal metabolism of stratum corneum lipids (6, 7).
Some congenital ichthyoses reveal abnormal deposition of apolar or
polar lipids or cholesterol in the intercorneocyte lipid layers, and
thereby appear to disrupt the normal lipid layerings and composition
required for effective epidermal barrier function (8). These include
recessive X-linked ichthyosis (XI) which is caused by an accumulation
of excess cholesterol 3-sulfate (CSO4) owing to
arylsulfatase C/cholesterol sulfatase enzyme defects (9).
CSO4 is a ubiquitous cholesterol metabolite, the amount of
which is determined by the relative activity of cholesterol
sulfotransferase and cholesterol sulfatase enzymes (10).
CSO4 gradually accumulates during epidermal keratinocyte
differentiation, peaking normally at levels of 4-5% of total lipids
in the upper stratum granulosum and it is hydrolyzed in the cornified
layer, so that normal corneocyte scales contain less than 1%
CSO4 of total lipids (11, 12). In XI the lack of its
breakdown results in an elevated CSO4 content in the basal
and spinous layers, peaking at >10% (by weight) of total lipids in
the stratum corneum (13).
However, it is not yet clear how excessive epidermal CSO4
diminishes barrier function in the epidermis, and whether the mild increase of epidermal (water) permeability alone is sufficient to
account for the severe symptoms of the disease. Several published reports have addressed the alterations of physical properties of
corneocyte lipids from excess CSO4 (14-16). It has been
shown that CSO4 can cause phase separation of
cholesterol-fatty acid layers (14) and that the XI phenotype can be
ameliorated by topical cholesterol treatment (17). Thus it was
suggested that XI arises due to a defect of intercorneocyte lipid layer
formation. In a conceptually related argument, CSO4 was
shown to interfere with spontaneous sheet formation of epidermal lipids
in vivo, perhaps due to the strong charge of its sulfate
moiety conferring detergent properties to CSO4. Thus it was
theorized that CSO4 affects epidermal barrier function both
by deranging skin lipid layers and by replacing cholesterol in the
lipid sheets (16). In another study, it was proposed that since
CSO4 has trypsin and chymotrypsin inhibitory properties
in vitro, it might thereby affect breakdown of desmosomes,
thus causing retention hyperkeratosis and abnormal scaling (18).
Finally, more recently, it was demonstrated that CSO4 can
induce TGase 1 expression in cultured keratinocytes (19), but the
connection between excess TGase expression and disease etiology remains
unclear. CSO4 in keratinocyte membranes was shown to
activate the protein kinase C isoforms , , and , presumably by
direct allosteric effects on their tertiary structures. As these
membrane-bound enzymes are involved in the signaling pathways of
keratinocyte differentiation (20, 21), CSO4 could induce
TGase 1 expression in this way (19).
Mammalian TGases (glutamyl-amine aminotransferases, EC 2.3.2.13)
constitute an evolutionarily related family of
Ca2+-dependent enzymes (22). The catalytic
mechanism of TGases involves the release of ammonia from the reactive
glutamine residues, and the residual glutamyl moieties form an
acyl-enzyme thioester, a labile intermediate susceptible to
nucleophilic attack by primary amines, notably -amino groups from
protein bound lysines (forming N -( -glutamyl)lysine isopeptide
cross-links), or polyamines (resulting in
N,N'-bis( -glutamyl)polyamine cross-links (23,
24). However, the thioester intermediate can also be transferred to
primary alcohols (25, 26). We have shown that in the epidermis, the terminal ( ) hydroxyl group of -hydroxyceramides is an effective substrate for membrane-bound TGase 1, and this route links these lipids
to protein-bound glutamines by an ester bond (27). Lastly, water can
also enter the active site of TGases to attack the acyl-enzyme intermediate, which leads to a net deamidation of a reactive glutamine to a glutamic acid residue (28, 29).
Seven members of the TGase family have been identified in the human
genome so far, of which four (TGases 1, 2, 3, and X) are expressed in
the epidermis (30, 31), although to date only TGases 1 and 3 have
verified roles in CE assembly (32, 33). TGase 1 is expressed as a
106-kDa monomeric protein, which is constitutively
N-myristoylated and S-palmitoylated on its
amino-terminal 10-kDa domain, thereby directing the enzyme to plasma
membranes (34-36). Membrane-bound TGase 1 enzyme is essential for both
the assembly of the protein envelope by cross-linking CE structural proteins located in the intimate vicinity of the cellular membrane, and
the esterification of the -hydroxyceramides to proteins, primarily
involucrin (27). Genetic defects of TGase 1 cause the often devastating
disease lamellar ichthyosis (37, 38). The homozygous TGase 1 knock-out
mice show defective CE assembly and die from dehydration a few hours
after birth (39).
Involucrin is ubiquitously expressed in stratified squamous epithelia,
suggesting it is commonly involved in CE formation (40, 41). Mammalian
involucrins evolved by tandem duplications of glutamine and glutamic
acid-rich sequences spanning between the evolutionary relatively
conserved amino-terminal ("head") and carboxyl-terminal
("tail") domains (42). Recent in vivo observations
indicate that the CE formation may be initiated by the deposition of a
monomolecular layer of involucrin on the inner keratinocyte membrane
(41, 43). In a previous paper (44) we described an in vitro
model system for characterizing the function of TGase 1 on the surface
of synthetic lipid vesicles (SLV) of composition similar to eukaryote
plasma membranes. Using this model system we have demonstrated that
involucrin is absorbed to membranes containing physiological levels of
phosphatidylserine at Ca2+ concentrations in the range
typically seen in keratinocytes.
Applying our SLV experimental system for modeling the earliest stages
of CE assembly, we demonstrate here that supraphysiological levels of
CSO4 severely interfere with involucrin cross-linking and
-hydroxyceramide esterification by TGase 1. Our data reveal new
insights into the pathophysiology of XI disease.
 |
MATERIALS AND METHODS |
Production of Recombinant TGase 1 and Human
Involucrins--
Full-length human TGase 1 and involucrin proteins
were expressed and purified exactly as described (44). A K62N mutant
form of human involucrin was made from the pET11a expression
plasmid by use of the
GCACATGACTGCTGTAACGGGACTGCCTGAGCAAGAATG primer and its
reverse strand using the QuickChange (Stratagene) kit, and further
processed identically to the wild type. Occasionally, involucrin
expression was induced in a LB broth containing 100 nmol (0.5 mCi/liter) of L-[35S]cysteine and 100 nmol
(0.5 mCi/liter) of L-[35S]methionine (both
from Amersham Pharmacia Biotech).
Preparation of SLV--
The following mixtures were made in
chloroform/methanol (2:1): 55 mol % dimyristoyl phosphatidylcholine,
15 mol % dipalmitoyl phosphatidylserine, 0-10 mol % CSO4, cholesterol up to 99 mol % (all from Sigma), and 1 mol % of the synthetic ceramide analog N-[16-(16-hydroxyhexadecyl)oxypalmitoyl]sphingosine (lipid
Z) (27). The solvent was evacuated, and the lipids were taken up in
aqueous buffer and dispersed by sonication as before (44). The prepared
SLV suspension was equipped with 0.94 pmol (0.1 µg) of TGase 1 and
its membrane binding was facilitated by incubating at 37 °C for 15 min prior to adding substrates.
Cross-linking of Involucrin by TGase 1--
SLV (200 µl, 2 µmol of lipid) formulated with 0-10 mol % CSO4 were
loaded with TGase 1 as above and 600 pmol (40 µg) of involucrin in
the presence of 1 mM CaCl2. They were
immediately incubated for 2 h in either the absence or presence of
20 mM putrescine with 100 nCi of
[14C]putrescine (NEN Life Science Products Inc., Boston,
MA, 110 Ci/mmol). The reactions were stopped by the addition of EDTA to 10 mM. In control experiments we assessed whether the
applied concentrations of CSO4 disrupted or aggregated the
SLV. SLV confectioned with 0-15 mol % CSO4 and the above
ingredients in various combinations were diluted 10-fold in reaction
buffer (without isotope) and examined by light scattering at 310 nm. As
we found no changes in light scattering for CSO4
concentrations below 12 mol %, we routinely used SLV containing 10
mol % CSO4.
Analysis of Cross-linking of Involucrin by TGase 1--
The
above reaction mixtures were diluted with SDS-PAGE sample buffer (45),
boiled, and analyzed by autoradiography after transfer onto
polyvinylidene difluoride membranes following SDS-PAGE on 4-20%
gradient gels (Novex). In some experiments, 0.1 ml of 20% SDS was
added to the samples and the mixture was vortexed. This mixture was
precipitated and washed three times with acetone/triethylamine/acetic acid (90:5:5) (46) to remove the SDS and noncovalently bound lipids.
After further washing with acetone, the pellet was dried under vacuum
and redissolved in 50 mM Tris-HCl (pH 7.5). Quantitation of
the N -( -glutamyl) lysine isopeptide
cross-link was done by amino acid analysis following exhaustive
proteolytic fragmentation of the products by the nonspecific protease
Pronase and a mixture of carboxypeptidases (47).
Determination of Kinetic Parameters of 14C-Putrescine
Incorporation by TGase 1--
Vmax,
Km, and kcat values were
determined exactly as described (44).
Isolation and Quantitation of Lipid Z Esterification of
Involucrin Reactive Glutamines by TGase 1--
The tryptic peptides of
involucrin reacted with TGase 1 on SLV formulated with 1% lipid Z for
2 h were recovered and quantitated exactly as described (27).
Analysis of Cross-linking and Deamidation of TGase 1 Reactive
Glutamine Residues in Involucrin--
There are four different
outcomes of TGase catalysis of reactive Gln residues in the present
experimental system, and are as follows: deamidated (that is, a Glu
residue is formed); ester-linked to the synthetic ceramide analog lipid
Z; and isopeptide cross-linked, either to the
N -amino group of an involucrin Lys residue
or, where added, to the diamine substrate putrescine forming
-glutamylputrescine (EP). Finally some substrate glutamine residues
are recovered in unmodified form. The following procedures were
designed to separately identify and quantitate each of these five end
products. Samples of TGase 1-reacted involucrin were freed from SLV
lipids as above. The protein was then digested with 2% (by weight)
modified trypsin (Roche Molecular Biochemicals). The grossly different chromatographic properties of
N -Lys62 cross-linked and lipid
Z-linked tryptic involucrin peptides allowed their separation and
quantitation by amino acid analysis following acid hydrolysis. In the
samples reacted with lipid Z, first the digest was passed through a
C4 HPLC column under strongly desorbing solvent conditions
as described (27), where only the lipopeptides are retarded and all
other non-lipid-containing peptides are recovered in the column
flow-through (4). The amount of the five lipid Z-ester linked peptides
(see Fig. 5A) was determined by amino acid analysis. The
peptide pool recovered from the C4 column flow-through was
further separated by C18 HPLC chromatography as described (44). Here peptides involved in cross-link formation were recovered as
distinct peaks (P1 and P2 of Fig. 2B) when cross-linked to another involucrin peptide. Sequences and cross-linking sites of these
peptides were determined by peptide sequencing as before (48). To
eliminate interference of overlapping (non-cross-linked) tryptic
peptides of involucrin, the absolute molar amount of cross-linked residues was calculated from the Thr content, since Thr was absent from
neighboring contaminating peptide peaks and was equimolar with the
N- ( -glutamyl)lysine isopeptide present in
the cross-linked peptide (Table I).
However, the peptides harboring unmodified, deamidated or
putrescine-linked glutamine residues were not resolvable by HPLC but
instead were analyzed by peptide sequencing. After Edman degradation, the phenylthiohydantoin-derivatized residues each appeared as a
distinct peak in the sequencer's HPLC profile (see Fig. 6). The ratio
of deamidation and putrescine cross-linking was determined from the
relative intensity of PITC/phenylthiohydantoin-derivatized Gln, Glu,
and EP peaks from the sequencing cycles corresponding to each expected
Gln residue as four of the reactive Gln residues were preceded by an
unreactive Gln, the ratio of the unmodified and deamidated Gln/Glu
residues was corrected for carryover from the previous sequencing cycle
of Gln, using the formula,
|
(Eq. 1)
|
where Xn denotes the amount of the amino acid
released from the sequencing cycle corresponding to the reactive
residue position, and Xn 1, or
Xn+1 denote the yield of the same amino
acid in the previous or consecutive sequencing cycle. Similarly, the
amount of EP was corrected for incomplete cleavage and carryover by the
formula,
|
(Eq. 2)
|
Where EPn denotes the amount of -glutamylputrescine
in the first cycle of its appearance and EPn+1 is
that from the next cycle. Molar absorption of EP was taken equal to
that of Lys at the detection wavelength of the Porton 3000 sequencer
(268 nm). Thus based on the directly measured absolute amounts of Gln
residues occupied by the
N -( -glutamyl)lysine cross-link and the
lipid Z ester, we could calculate from the sequencing chromatograms the
fate of the remainder of the 600 pmol of the Gln residues of involucrin
that was unreacted, deamidated, and in control experiments,
putrescine-linked. The data represent the means of three or more
independent measurements.
 |
RESULTS AND DISCUSSION |
Involucrin is Cross-linked to Itself by TGase 1 on SLV--
Wild
type 35S-involucrin was reacted with TGase 1 on the surface
of SLV for 2 h in the absence of exogenous glutamyl acceptor substrates. The protein was cross-linked into dimers, trimers, tetramers, and higher oligomers, as evidenced by autoradiography of
protein blots after separation by SDS-PAGE (Fig.
1A). Some of the protein
showed faster electrophoretic mobility than the monomer, indicative of
intramolecular cross-link formation (49). Oligomers larger than
tetramers were not separated by the gels used, but remained at the
interface of the separation gel. Inclusion of 1 mol % lipid Z into the
SLV membranes did not eliminate involucrin cross-linking by TGase 1 (Fig. 1B), but the addition of 20 mM putrescine
as a competitive inhibitor of protein bound lysine -amino groups
(Fig. 1C) or omission of Ca2+ (not shown) caused
a virtually complete inhibition of oligomer formation. These data
indicate that involucrin is a complete substrate for the TGase 1 enzyme
bound to SLV, in that it provides both donor Gln and acceptor Lys
residues, and confirm a similar conclusion for the reaction of crude
TGase 1 with involucrin in solution assays (49).

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 1.
Cross-linking of involucrin by TGase 1 on
SLV. Recombinant human 35S-involucrin was incubated
with TGase 1 attached to SLV containing 15% phosphatidylserine (and no
CSO4) in the presence of Ca2+ for 60 min.
20-µg aliquots of involucrin products were separated by SDS-PAGE,
transferred onto membranes, and detected by autoradiography.
A, involucrin formed intrachain cross-links (I),
dimers (D), trimers (T), and unresolved higher
oligomers (O). B, cross-linking of involucrin was
not impeded by the inclusion of 1 mol % lipid Z ceramide substrate;
C, oligomerization was inhibited by 20 mM
putrescine. D, in the case of the K62N mutant form of
involucrin, no cross-linking occurred.
|
|
TGase 1 Forms Intermolecular Cross-links between Lys62
and Gln496 or Gln133 Residues of
Involucrin--
In order to identify the residues involved in the
oligomerization by cross-linking of involucrin, following TGase 1 reaction on SLV and fragmentation by trypsin, peptides were separated
by C18 reverse-phase HPLC, and the elution profile of
obtained peptide peaks was compared with that of the uncross-linked
protein (44) (Fig. 2, A and
B). The cross-linking by TGase 1 caused the appearance of
two novel peaks (P1 and P2 on Fig. 2B), and concomitant
reduction of the relative intensity of three peaks compared with the
initial profile. Protein sequencing revealed that the novel peaks
resulted from cross-link formation of two Gln donor peptides with a
single Lys (Table I) and that the
residues involved in N -( -glutamyl)lysine
cross-linking were Gln496 or Gln133 with
Lys62, respectively. No other novel potentially
cross-linked peaks with yields >0.005 mol/mol of involucrin were
found. Given the large numbers of Gln and Lys residues in involucrin
(50), this remarkable degree of specificity leading to both
head-to-tail and head-to-head oligomerization provides further evidence
for the importance of the membrane surface in directing TGase 1 specificity. Identical results were obtained if 1 mol % lipid Z
incorporated into SLV was offered as an alternative glutaminyl acceptor
substrate (data not shown), in agreement with previous findings that
isopeptide bonds formed by amine substrates are energetically more
favored products of TGase catalysis that ester bonds (27).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 2.
Identification of cross-linking sites in
involucrin. C18 HPLC profiles of tryptic involucrin
peptides were compared before (A) and after (B)
reaction with TGase 1 bound to SLV containing no CSO4.
Peaks harboring the 5 Gln residues reactive with SLV-bound TGase 1 are
indicated with arrows on panel A. For clarity,
the same peak numbering system was retained as before (44). TGase
1-dependent appearance of the novel peaks P1
and P2 is noted. The sequences of these peaks are shown in
Table I.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Amino acid sequences of peptide peaks from HPLC separation of tryptic
involucrin peptides (Fig. 2B) affected by cross-linking by TGase
1 on SLV
|
|
Interestingly, Lys62 has been precisely conserved in all
mammalian involucrins (42), inferring that oligomerization through this
residue is an ancient aspect of CE formation. However, cross-links involving Lys62 were not found in CEs recovered from mature
foreskin epidermal stratum corneum tissue (41), but cross-links between
Lys62 and Gln496 or Gln133 were
commonly observed in CEs formed in cultured keratinocytes (51).
Likewise, although Gln133 is not conserved in prosimians
(42), cross-linked peptides involving it were found in cultured
keratinocyte CEs. As these keratinocytes undergo only a limited degree
of barrier formation, we can conclude that cross-linking though
Lys62 or Gln133 should represent early stages
of CE assembly, and that the numerous other Lys and Gln residues
identified in our in vivo studies must be utilized in later
stages (51).
K62N Mutant Involucrin Is Not Oligomerized by SLV-Bound TGase
1--
As a control for the cross-linking through the sole
Lys62 residue, we made a K62N mutant form of involucrin.
This completely eliminated the ability of involucrin to serve as
complete substrate for TGase 1 on SLV, as autoradiography after
SDS-PAGE showed no detectable inter- or intrachain cross-linked
involucrin products (Fig. 1D). Likewise, the HPLC profile of
tryptic peptides of the involucrin mutant showed no sign of the TGase
1-mediated changes which were observed with the wild type protein
(although as expected, peak 9 disappeared since a trypsin cleavage site
was lost as a consequence of the mutation, and another new peak
appeared (data not shown)).
Effect of CSO4 Content in SLV on Involucrin
Cross-linking by TGase 1--
The effect of CSO4 on the
membrane-dependent cross-linking of involucrin was examined
by formulating the carrier SLV with 0-10 mol % CSO4 in
2% increments. CSO4 concentrations above 12% began to
destabilize SLV assembly and therefore were not used. Analysis of the
electrophoretic mobility of TGase 1-treated 35S-involucrin
revealed a CSO4 concentration-dependent
inhibition of cross-linking, which was apparent at 6 mol % and almost
completely eliminated the bands of inter- or intramolecularly
cross-linked involucrin at 10% (Fig.
3A). Assaying the amounts of
N -( -glutamyl)lysine isopeptide cross-link
showed a significant decline of cross-link amount at 6 mol % CSO4 (p < 0.001) and which was reduced to
<10% at 10 mol % CSO4 (Fig. 3B).

View larger version (67K):
[in this window]
[in a new window]
|
Fig. 3.
Increasing amounts of CSO4
inhibits of involucrin cross-linking. Formation of cross-linked
oligomers from involucrin was analyzed at different SLV membrane
CSO4 concentrations as in Fig. 1. Reduction of cross-linked
products is apparent above 6 mol % CSO4.
|
|
TGase 1 activity was assayed by using a large excess of
[14C]putrescine as the amine substrate with both
involucrin and the standard TGase assay substrate succinylated casein.
Incorporation of the labeled amine was not significantly affected at
any concentration below 8 mol % CSO4 and only a slight
decrease (p < 0.1) of activity was noted at 10 mol % (Fig. 4A). Kinetic parameters
of [14C]putrescine incorporation into involucrin and the
standard substrate succinylated casein, which does not adsorb to SLV
under these conditions (44) were measured (Table
II), and indicated that up to 10 mol % CSO4 there was no statistically significant
(p < 0.1) change in the apparent
Vmax of TGase 1. However, when 1 mM
putrescine was used, SLV CSO4 content caused a
dose-dependent decrease of the reaction rate. The assay of
kinetic parameters revealed only an insignificant effect of
CSO4 on Vmax with both protein
substrates. However, for the substrate putrescine, membrane CSO4 caused a dose-dependent increase of
Km(app) and thus reduced the catalytic
efficiency (Kcat/KM) values, a
phenomenon characteristic of competitive inhibition.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 4.
Activity of membrane-bound TGase 1 at
different SLV CSO4 concentrations measured by
[14C]putrescine incorporation. A,
radioactive putrescine incorporation into involucrin
(circles) and succinylated casein (triangles)
substrates showed no significant (p < 0.05) dependence
from membrane CSO4 levels under standard assay conditions,
when [14C]putrescine was given at 20 mM
concentration. However, if 1 mM putrescine was used instead
(B), the inhibition of activity was apparent at 5 or higher
mol % membrane CSO4. The phenomenon is indicative of
competitive inhibition.
|
|
View this table:
[in this window]
[in a new window]
|
Table II
Apparent kinetic parameters for putrescine incorporation into
involucrin and succinylated casein by 0.94 pmol membrane bound TGase 1 at different membrane CSO4 concentrations
All SLV were formulated with 55% phosphatidylcholine and 15%
phosphatidylserine. KM(app) values pertain
to the protein, unless otherwise stated. Vmax and
Kcat data are that of putrescine incorporation.
Values with 0% CSO4 are the same as published before (30).
|
|
Effect of SLV Content of CSO4 on -Hydroxyceramide
Esterification by TGase 1--
In addition, we explored the effects of
CSO4 on TGase 1-mediated -hydroxyceramide attachment to
involucrin by esterification. One mol % of the artificial
-hydroxyceramide analog lipid Z was incorporated into the SLV and
reacted with involucrin by TGase 1 as before (27). Isolation of
peptide-linked ceramides was done by C4 HPLC separation of
tryptic peptides of involucrin under strongly desorbing solvent
conditions, where only the lipopeptide adducts are retarded and free
peptides elute with the column flow-through (4). Amounts of recovered
peptide-lipid Z adducts showed a visible decline of peak areas in SLV
containing 4 mol % CSO4 content (Fig.
5A). Quantitative analysis of
these peaks by amino acid analysis after acid hydrolysis indicated a
significant decrease of summed lipopeptide formation at 4 mol % (p < 0.001) SLV CSO4 content, a 10-fold
reduction at 8 mol %, and >30-fold less with 10 mol % CSO4 (Fig. 5B).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 5.
Increasing amounts of CSO4
inhibits of involucrin esterification. Involucrin was reacted with
TGase 1 on SLV confectioned with 1 mol % of the -hydroxyceramide
analog lipid Z and 0-10 mol % CSO4. Lipid Z esterified
onto involucrin was quantitated by isolating tryptic lipopeptides by
C4 HPLC (27). A, reduction of lipopeptide peaks
with increasing CSO4 is shown by superimposing the
chromatograms of lipopeptides selectively retained on the column from
the tryptic digest of 60 µg of involucrin labeled with lipid Z by
TGase 1 on SLV with 0 (red line), 4 (orange
line), and 8 (yellow line) mol % CSO4.
Quantitation of these reactions (B) revealed a significant
decline of involucrin esterification by lipid Z at 3 (*,
p < 0.1) or 4 (**, p < 0.01) mol % SLV CSO4 content.
|
|
Taken together, the inhibition of isopeptide cross-linking and ester
formation imply that CSO4 serves as a competitive inhibitor of TGase 1 reactions. However, since CSO4 is clearly not a
substrate for TGases, it is possible that instead it interferes with
the reaction by limiting access to the active site for substrates or by
conformational alteration of the enzyme. In order to resolve these
issues in detail, we analyzed the fate(s) of each reactive Gln residue
using different substrate conditions.
Analysis of TGase 1-mediated Modifications of Reactive Gln Residues
in Involucrin with Increasing SLV CSO4 Content--
Five
Gln residues (Gln107, Gln118,
Gln122, Gln133, and Gln496) of
involucrin serve as substrates for membrane-bound TGase 1 (27, 44). Each of these Gln residues can undergo either hydrolysis or ester bond
formation or transglutamination as one of four fates of each reactive
Gln residue, we formulated SLV with different membrane CSO4
contents, and used the following different substrate conditions: wild
type involucrin or its K62N mutant were reacted either with only
itself, or with 1 mol % lipid Z in SLV. As controls, we also used 20 mM putrescine as a competitive inhibitor, in which case the
EP derivative is formed.
Following reaction, involucrin was fragmented with trypsin, and where
applicable, lipid Z-attached peptides were extracted from the peptide
pool by selective retardation on the C4 HPLC column (Fig.
5A). Lipopeptides were quantified by amino acid analysis following acid hydrolysis. The remainder of the peptides was
lyophilized and separated by C18 HPLC. Peaks harboring
reactive Gln residues were collected based on their known
chromatographic elution properties (44). Peaks of cross-linked peptides
(Fig. 2B) were also collected and quantified. The peaks
harboring TGase 1-reactive glutamines embraced a mixture of
glutamine-derived moieties, that were either unmodified, deamidated to
glutamic acid, or eventually modified to EP. These products were
collected in the same fraction, and sequenced as a mixture. The
phenylthiohydantoin-derivatives of Gln, Glu, and EP from TGase 1 substrate residues Gln107, Gln118,
Gln122, Gln133, and Gln496 were
measured in the appropriate sequencing cycles (Fig.
6) and peak area derived absolute molar
amount values were corrected for carryover from previous cycles,
spontaneous deamidation, and coupling yield by pristine algebra. Data
for all five glutamines are summarized in Table
III.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 6.
An assay for the rate of deamidation and
putrescine cross-linking of reactive Gln residues by protein
sequencing. The figure shows superimposed elution chromatograms of
residue Gln133 recovered from peptide peak 22 (see Fig.
2A) of involucrin reacted with TGase 1 in the presence of 20 mM putrescine on SLV made with 0 (black line) or
8 mol % (red line) membrane CSO4. Peak areas
were utilized to calculate the ratio of different Gln modifications by
TGase 1.
|
|
View this table:
[in this window]
[in a new window]
|
Table III
Distribution of products from substate glutamine residues of involucrin
after reacting with 0.94 pmol of TGase 1 on SLV formulated with
different CSO4 content
Values were calculated from amino acid analysis after acid hydrolysis
data combined with Gln:Glu (: -glutamylputrescine) ratios from
sequencing yields. Numbers represent mean of three determinations
rounded to whole percentage. NA, not available.
|
|
When wild type involucrin was reacted with TGase 1 on SLV formulated
without CSO4 in the absence of any other glutamyl-acceptor substrate, 51% of the Gln496 residue was modified, of
which most was engaged in cross-link formation with Lys62
(Fig. 7A). Inclusion of
increasing amounts of CSO4 into SLV greatly decreased the
percentage utilization of the Gln496 for cross-link
formation, but steadily increased the amount of deamidation, so that in
SLV with 10% CSO4, 53% was deamidated and only 8% was
used for cross-link formation. Similar deamidation rates were seen for
the Gln133 residue which also participated in cross-link
formation. For Gln107, Gln118, and
Gln122 which did not engage in
N -( -glutamyl)lysine cross-link formation
with Lys62, most was likewise deamidated (Fig.
7G, other data not shown). Next, we used SLV containing 1 mol % of the synthetic -hydroxyceramide substrate lipid Z. In the
case of Gln496, 1 mol % lipid Z could not effectively
compete out the isopeptide cross-link formation, but about 5% was used
for ester formation in the absence of CSO4 (27) (Fig.
7B). However, all was lost to deamidation by 6% membrane
CSO4. For Gln107, Gln118,
Gln122, and Gln133, 20-30% was used for ester
formation in the absence of CSO4, and again, an increasing
percentage of deamidation eradicated this reaction product by 8-10 mol
% CSO4 (Fig. 7H for Gln122, other
data not shown). Finally, addition of 20 mM putrescine to
the above system led to near complete modification of
Gln496 to EP and efficiently suppressed the cross-linking
and deamidation by TGase 1 as expected (44). Even so, there was a small
but significant increase in deamidation rate at the highest levels of
CSO4 tested (Fig. 7C). Essentially identical
results were seen with the other four reactive Gln residues (Fig.
7I; Table III).

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 7.
The fates of TGase 1 reactive residues
Gln496 and Gln122 of involucrin with different
substrates at increasing membrane CSO4 levels. The
degrees of modifications of each Gln residue were quantitated as
determined in Figs. 5A and 6. Shown here are the data for
the most reactive Gln496 residue (A-F), which
participates in both isopeptide and ester bond formation, and for
Gln122 (G-L) which is involved only in ester
formation under physiologically relevant conditions. The applied
substrates and color codes are noted for each panel.
|
|
When the K62N mutant form of involucrin was reacted with TGase 1 in the
absence of any other glutamyl-acceptor substrate, water was used as the
acyl acceptor resulting in near complete (80-90%) deamidation of the
five reactive Gln residues, the degree of which was not significantly
increased with higher CSO4 levels (Fig. 7, D and
J; Table III). In this case, about 10% of the reactivity of
each Gln residue was used for esterification of lipid Z in the absence
of CSO4, but this was lost to deamidation at 6 mol % CSO4 (Fig. 7, E and K). Again, the
inclusion of 20 mM putrescine into the reactions resulted
in extensive EP formation as expected, although with increasing amounts
of CSO4, the ratio between EP formation and deamidation was
reduced significantly and was essentially the same as with the wild
type involucrin (compare Fig. 7, F and L with
C and I).
These data indicate the glutamyl donor and acceptor substrate
preferences of involucrin cross-linking by membrane bound TGase 1. Of
these, only Gln496, Gln133, and
Lys62 can be used for
N -( -glutamyl)lysine cross-link formation,
but all the five reactive glutamines form isopeptide bonds and are
esterified with the ceramide-alcohol lipid Z. We propose that steric
factors might hinder the intimate juxtaposition of Lys62 to
the acyl-enzyme complex when involucrin reacts with TGase 1 on its
Gln107, Gln118, or
Gln122.
We also noted that cross-linking through Lys62 decreased
the overall degree of reactivity of the neighboring reactive Gln
residues, in comparison to the uncross-linkable mutant (Fig. 7, compare panels B and E). This might be a consequence of
the inhibition of substrate diffusion on the SLV surface following the
formation of larger involucrin oligomers, and/or the TGase 1 itself by
"stockading" the enzyme by its own products, a mechanism impossible
with the K62A mutant protein. Finally, cross-linking through
Lys62 increased the yield of especially Gln107,
Gln118, Gln122, and Gln133 for
esterification (Fig. 7, as examples, compare panels H and K), This might be a consequence of diminished likelihood for
TGase 1-mediated hydrolysis of ester bonds via reversal of once
preformed ester linkages to the acyl-enzyme intermediate, possibly by
the same stockading mechanism. We have noted previously that isopeptide formation is energetically favored over ester formation, since the
latter can be converted to an isopeptide bond by an amine (27). Thus it
is possible that once an isopeptide bond is, practically irreversibly
(52) formed through Lys62, which is located near the
reactive Gln residues in the head domain of involucrin, the bulk of the
cross-linked involucrins "saves" ester bonds from further
ester-hydrolase activity by TGase 1 enzyme.
How Does CSO4 Facilitate Deamidation of Reactive Gln
Residues?--
The most striking observation in the foregoing data is
that the presence of 6% CSO4 in SLV membranes markedly
diverts the TGase 1 reaction mechanism of Gln residues from isopeptide
or ester formation to deamidation. One possible mechanism for this phenomenon is that excess membrane CSO4 distorts the
structure of the glutamyl acceptor substrate binding pocket so as to
favor the access of water to the acyl-enzyme thioester intermediate. As
water is in great molar excess over other glutamyl acceptor substrates,
and the usage of water as a substrate is detectable under all assay
conditions using TGases (Fig. 7) (23, 29), it is to be expected that
even a slight conformational change should be sufficient to increase
the opportunity of water to attack the acyl-enzyme thioester
intermediate. The substrate binding pockets of TGases (based on
crystallographic data of factor XIIIa (34, 53)) are imagined as grooves
on the enzyme surface, permitting the binding of two protruding
residues on bulky proteins and the consecutive release of the
cross-linked dimer. The repelling of water from the active site is done
by several juxtaposed hydrophobic side chain residues surrounding the
active site, ideally making the concentration of water in the acceptor
substrate-binding groove equal to the concentration of water in the
saturated vapor of the reaction medium. In reality, the use of water
may prevent TGases from being trapped to their glutaminyl substrates in
the absence of other utilizable acceptors, so that this deamidation reaction route may have practical usefulness in regenerating the enzyme
after interaction with decoy substrates (29). CSO4 may thus
enhance the opportunity for this natural phenomenon.
Apparently the highest level of membrane CSO4 compatible
with near-optimal cross-link and ceramide ester formation is 6 mol %, which based on the distribution of total stratum granulosum lipids,
might be 4.5-5.5% by weight (54), although the actual local surface
density of this metabolite might be lower owing to dilution by plasma
membrane lipids or may be higher owing to the amphipathic character of
CSO4. Nevertheless, this estimate of 4.5-5.5% is right in
the range found in the lowest layers of normal stratum corneum, and is
severalfold less than that measured in XI epidermis (55).
Conclusions: Consequences for Pathogenesis of Ichthyosis
Diseases--
The precise mechanism by which excessive levels of
CSO4 cause defective skin barrier function and disease in
XI has heretofore not been well understood. It was proposed that since
CSO4 has trypsin and chymotrypsin inhibitory properties
in vitro, it might thereby affect breakdown of desmosomes,
thus causing retention hyperkeratoses and abnormal scaling (18). The
strong charge of its sulfate moiety conferring mild detergent
properties to CSO4 was shown to interfere with spontaneous
sheet-formation of epidermal lipids in vivo and thus
theorized to affect epidermal barrier function by deranging skin lipid
layers, repressing cholesterol synthesis, and replacing cholesterol in
the lipid sheets (16). More recently, it was demonstrated that
CSO4 can induce TGase 1 expression in cultured
keratinocytes (19), but the connection between excess TGase expression
and disease etiology remains unclear. Our present data offer an
alternative biochemical explanation as to how accumulation of
CSO4 may cause XI disease. We show that CSO4
inhibits the capacity of TGase 1 to perform isopeptide cross-linking as
well as ester linkage of ceramides. Decreased isopeptide bonding is
likely to disrupt the earliest stages of CE formation, by preventing cross-links between involucrin and desmoplakin or itself (41, 48) and
thus derange the consecutive series of steps required for protein
envelope formation. Furthermore, supraphysiological levels of
CSO4 inhibit lipid bound envelope formation and thus can
interfere with the appropriate orientation and mechanical stability of
the intercorneocyte lipid layers. In these ways, the net result is
comparable to loss of TGase 1 function as observed in lamellar
ichthyosis (34, 37, 38). Finally, it is possible that in addition to
XI, other skin diseases having an ichthyosiform phenotype may also
arise as a result of direct or indirect interference with effective
TGase 1 function.
 |
ACKNOWLEDGEMENTS |
We are indebted to William W. Idler for
expert assistance in expressing recombinant involucrins and are
grateful to Peter M. Elias for stimulating discussions.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Bldg. 6, Rm. 425, NIAMS, NIH, Bethesda, MD 20892-2752. Tel.: 301-496-1578; Fax: 301-402-2886; E-mail: pemast@helix.nih.gov.
 |
ABBREVIATIONS |
The abbreviations used are:
CE, cell envelope;
CSO4, cholesterol sulfate;
EP, -glutamylputrescine;
HPLC, high performance liquid chromatography;
lipid Z, N-[16-(16-hydroxyhexadecyl)oxypalmitoyl]sphingosine;
XI, X-linked ichthyosis;
SLV, synthetic lipid vesicles;
TGase, transglutaminase;
PAGE, polyacrylamide gel electrophoresis.
 |
REFERENCES |
| 1.
|
Nemes, Z.,
and Steinert, P. M.
(1999)
Exp. Mol. Med.
3,
5-19
|
| 2.
|
Ishida-Yamamoto, A.,
and Iizuka, H.
(1998)
Exp. Dermatol.
7,
1-10[Medline]
[Order article via Infotrieve]
|
| 3.
|
Wertz, P. W.,
and Downing, D. T.
(1991)
in
Physiology, Biochemistry and Molecular Biology of the Skin
(Goldsmith, L. A., ed), Vol. 1
, pp. 205-236, Oxford University Press, Oxford
|
| 4.
|
Marekov, L. N.,
and Steinert, P. M.
(1998)
J. Biol. Chem.
273,
17763-17770[Abstract/Free Full Text]
|
| 5.
|
Wertz, P. W.
(1997)
Exper. Suppl. (Basel)
78,
227-237
|
| 6.
|
Steinberg, D. S.
(1978)
in
The Metabolic Basis of Inherited Disease
(Stanbury, J. B.
, Wyngaarden, J. B.
, and Frederickson, D. S., eds), 4th Ed.
, pp. 688-691, McGraw-Hill, New York
|
| 7.
|
De Laurenzi, V.,
Rogers, G. R.,
Hamrock, D. J.,
Marekov, L. N.,
Steinert, P. M.,
Compton, J. G.,
Markova, N.,
and Rizzo, W. B.
(1996)
Nat. Genet.
12,
52-57[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Anton-Lamprecht, I.
(1992)
in
Diagnostic Ultrastructure of Non-neoplastic Diseases
(Papadimitrou, J. M.
, Henderson, D. W.
, and Spagnolo, D. V., eds)
, pp. 459-551, Churchill Livingstone, New York
|
| 9.
|
Shapiro, L. J.,
Weiss, R.,
Buxman, M. M.,
Vidgoff, J.,
Dimond, R. L.,
Roller, J. A.,
and Wells, R. S.
(1978)
Lancet
2,
756-757[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Epstein, E. H.,
Williams, M. L.,
and Elias, P. M.
(1984)
J. Am. Acad. Dermatol.
10,
866-868[Medline]
[Order article via Infotrieve]
|
| 11.
|
Ranasinghe, A. W.,
Wertz, P. W.,
Downing, D. T.,
and Mackenzie, I. C.
(1986)
J. Invest. Dermatol.
86,
187-190[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Long, S. A.,
Wertz, P. W.,
Strauss, J. S.,
and Downing, D. T.
(1985)
Arch Dermatol. Res.
277,
284-287[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Williams, M. L.
(1992)
Semin. Dermatol.
11,
169-175[Medline]
[Order article via Infotrieve]
|
| 14.
|
Rehfeld, S. J.,
Williams, M. L.,
and Elias, P. M.
(1986)
Arch Dermatol. Res.
278,
259-263[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Rehfeld, S. J.,
Plachy, W. Z.,
Williams, M. L.,
and Elias, P. M.
(1988)
J. Invest. Dermatol.
91,
499-505[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Zettersten, E.,
Man, M. Q.,
Sato, J.,
Denda, M.,
Farrell, A.,
Ghadially, R.,
Williams, M. L.,
Feingold, K. R.,
and Elias, P. M.
(1998)
J. Invest. Dermatol.
111,
784-790[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Lykkesfeldt, G.,
and Hoyer, H.
(1983)
Lancet
2,
1337-1338[Medline]
[Order article via Infotrieve]
|
| 18.
|
Sato, J.,
Denda, M.,
Nakanishi, J.,
Nomura, J.,
and Koyama, J.
(1998)
J. Invest. Dermatol.
111,
189-193[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Kawabe, S.,
Ikuta, T.,
Ohba, M.,
Chida, K.,
Ueda, E.,
Yamanishi, K.,
and Kuroki, T.
(1998)
J. Invest. Dermatol.
111,
1098-1102[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Chida, K.,
Murakami, A.,
Tagawa, T.,
Ikuta, T.,
and Kuroki, T.
(1995)
Cancer Res.
55,
4865-4869[Abstract/Free Full Text]
|
| 21.
|
Ikuta, T.,
Chida, K.,
Tajima, O.,
Matsuura, Y.,
Iwamori, M.,
Ueda, Y.,
Mizuno, K.,
Ohno, S.,
and Kuroki, T.
(1994)
Cell Growth Differ.
5,
943-947[Abstract]
|
| 22.
|
Polakowska, R. R.,
Eickbush, T.,
Falciano, V.,
Razvi, F.,
and Goldsmith, L. A.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
4476-4480[Abstract/Free Full Text]
|
| 23.
|
Folk, J. E.,
and Finlayson, J. S.
(1977)
Adv. Protein Chem.
31,
1-133[Medline]
[Order article via Infotrieve]
|
| 24.
|
Greenberg, C. S.,
Birckbichler, P. J.,
and Rice, R. H.
(1991)
FASEB J.
5,
3071-3077[Abstract]
|
| 25.
|
Gross, M.,
and Folk, J. E.
(1974)
J. Biol. Chem.
249,
3021-3025[Abstract/Free Full Text]
|
| 26.
|
Parameswaran, K. N.,
and Lorand, L.
(1981)
Biochemistry
20,
3703-3711[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Nemes, Z.,
Marekov, L. N.,
Fésüs, L.,
and Steinert, P. M.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
8402-8407[Abstract/Free Full Text]
|
| 28.
|
Folk, J. E.,
and Chung, S. I.
(1985)
Methods Enzymol.
113,
358-375[Medline]
[Order article via Infotrieve]
|
| 29.
|
Folk, J. E.,
and Chung, S. I.
(1973)
Adv. Enzymol. Relat. Areas Mol. Biol.
38,
109-191[Medline]
[Order article via Infotrieve]
|
| 30.
|
Rice, R. H.,
Mehrpouyan, M.,
Qin, Q.,
and Phillips, M. A.
(1994)
in
The Keratinocyte Handbook
(Leigh, I. M.
, Lane, E. B.
, and Watt, F. M., eds)
, pp. 259-274, Cambridge University Press, Cambridge
|
| 31.
|
Aeschlimann, D.,
Koeller, M. K.,
Allen-Hoffmann, B. L.,
and Mosher, D. F.
(1998)
J. Biol. Chem.
273,
3452-3460[Abstract/Free Full Text]
|
| 32.
|
Candi, E.,
Melino, G.,
Mei, G.,
Tarcsa, E.,
Chung, S. I.,
Marekov, L. N.,
and Steinert, P. M.
(1995)
J. Biol. Chem.
270,
26382-26390[Abstract/Free Full Text]
|
| 33.
|
Tarcsa, E.,
Candi, E.,
Kartasova, T.,
Idler, W. W.,
Marekov, L. N.,
and Steinert, P. M.
(1998)
J. Biol. Chem.
273,
23297-23303[Abstract/Free Full Text]
|
| 34.
|
Candi, E.,
Melino, G.,
Lahm, A.,
Ceci, R.,
Rossi, A.,
Kim, I. G.,
Ciani, B.,
and Steinert, P. M.
(1998)
J. Biol. Chem.
273,
13693-13702[Abstract/Free Full Text]
|
| 35.
|
Steinert, P. M.,
Kim, S. Y.,
Chung, S. I.,
and Marekov, L. N.
(1996)
J. Biol. Chem.
271,
26242-26250[Abstract/Free Full Text]
|
| 36.
|
Rice, R. H.,
Rong, X. H.,
and Chakravarty, R.
(1990)
Biochem. J.
265,
351-357[Medline]
[Order article via Infotrieve]
|
| 37.
|
Russell, L. J.,
DiGiovanna, J. J.,
Rogers, G. R.,
Steinert, P. M.,
Hashem, N.,
Compton, J. G.,
and Bale, S. J.
(1995)
Nat. Genet.
9,
279-283[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Huber, M.,
Rettler, I.,
Bernasconi, K.,
Frenk, E.,
Lavrijsen, S. P.,
Ponec, M.,
Bon, A.,
Lautenschlager, S.,
Schorderet, D. F.,
and Hohl, D.
(1995)
Science
267,
525-528[Abstract/Free Full Text]
|
| 39.
|
Matsuki, M.,
Yamashita, F.,
Ishida-Yamamoto, A.,
Yamada, K.,
Kinoshita, C.,
Fushiki, S.,
Ueda, E.,
Morishima, Y.,
Tabata, K.,
Yasuno, H.,
Hashida, M.,
Iizuka, H.,
Ikawa, M.,
Okabe, M.,
Kondoh, G.,
Kinoshita, T.,
Takeda, J.,
and Yamanishi, K.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
1044-1049[Abstract/Free Full Text]
|
| 40.
|
Eckert, R. L.,
Yaffe, M. B.,
Crish, J. F.,
Murthy, S.,
Rorke, E. A.,
and Welter, J. F.
(1993)
J. Invest. Dermatol.
100,
613-617[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Steinert, P. M.,
and Marekov, L. N.
(1997)
J. Biol. Chem.
272,
2021-2030[Abstract/Free Full Text]
|
| 42.
|
Green, H.,
and Djian, P.
(1992)
Mol. Biol. Evol.
9,
977-1017[Abstract]
|
| 43.
|
Jarnik, M.,
Simon, M. N.,
and Steven, A. C.
(1998)
J. Cell Sci.
111,
1051-1060[Abstract]
|
| 44.
|
Nemes, Z.,
Marekov, L. N.,
and Steinert, P. M.
(1999)
J. Biol. Chem.
274,
11013-11021[Abstract/Free Full Text]
|
| 45.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Konigsberg, W. H.,
and Henderson, L.
(1983)
Methods Enzymol.
91,
254-259[Medline]
[Order article via Infotrieve]
|
| 47.
|
Tarcsa, E.,
and Fesus, L.
(1990)
Anal. Biochem.
186,
135-140[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Steinert, P. M.,
and Marekov, L. N.
(1995)
J. Biol. Chem.
270,
17702-17711[Abstract/Free Full Text]
|
| 49.
|
LaCelle, P. T.,
Lambert, A.,
Ekambaram, M. C.,
Robinson, N. A.,
and Eckert, R. L.
(1998)
Skin Pharmacol. Appl. Skin Physiol.
11,
214-226[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Eckert, R. L.,
and Green, H.
(1986)
Cell
46,
583-589[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Steinert, P. M.,
and Marekov, L. N.
(1999)
Mol. Cell. Biol.
10,
4247-4261
|
| 52.
|
Parameswaran, K. N.,
Cheng, X. F.,
Chen, E. C.,
Velasco, P. T.,
Wilson, J. H.,
and Lorand, L.
(1997)
J. Biol. Chem.
272,
10311-10317[Abstract/Free Full Text]
|
| 53.
|
Yee, V. C.,
Pedersen, L. C.,
Le Trong, I.,
Bishop, P. D.,
Stenkamp, R. E.,
and Teller, D. C.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
7296-7300[Abstract/Free Full Text]
|
| 54.
|
Williams, M. L.
(1991)
Adv. Lipid Res.
24,
211-262[Medline]
[Order article via Infotrieve]
|
| 55.
|
Elias, P. M.,
Williams, M. L.,
Maloney, M. E.,
Bonifas, J. A.,
Brown, B. E.,
Grayson, S.,
and Epstein, E. H., Jr.
(1984)
J. Clin. Invest.
74,
1414-1421
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. E. Iismaa, B. M. Mearns, L. Lorand, and R. M. Graham
Transglutaminases and Disease: Lessons From Genetically Engineered Mouse Models and Inherited Disorders
Physiol Rev,
July 1, 2009;
89(3):
991 - 1023.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M. Elias, M. L. Williams, W. M. Holleran, Y. J. Jiang, and M. Schmuth
Thematic review series: Skin Lipids. Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism
J. Lipid Res.,
April 1, 2008;
49(4):
697 - 714.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. B. Javitt, Y. C. Lee, C. Shimizu, H. Fuda, and C. A. Strott
Cholesterol and Hydroxycholesterol Sulfotransferases: Identification, Distinction from Dehydroepiandrosterone Sulfotransferase, and Differential Tissue Expression
Endocrinology,
July 1, 2001;
142(7):
2978 - 2984.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Candi, S. Oddi, A. Terrinoni, A. Paradisi, M. Ranalli, A. Finazzi-Agro, and G. Melino
Transglutaminase 5 Cross-links Loricrin, Involucrin, and Small Proline-rich Proteins in Vitro
J. Biol. Chem.,
September 7, 2001;
276(37):
35014 - 35023.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|